- Home
- NUVL
NUVL
Nuvalent Inc.
as 04-25-2025 4:00pm EST
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.6B | IPO Year: | 2021 |
| Target Price: | $115.50 | AVG Volume (30 days): | 682.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $55.54 - $113.51 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Porter James Richard | NUVL | President and CEO | Apr 15 '25 | Sell | $69.54 | 27,000 | $1,861,504.46 | 249,550 | |
| Noci Darlene | NUVL | Chief Development Officer | Mar 27 '25 | Sell | $73.37 | 4,000 | $292,468.00 | 48,934 | |
| Porter James Richard | NUVL | President and CEO | Mar 17 '25 | Sell | $76.06 | 27,000 | $2,048,561.73 | 249,550 | |
| Noci Darlene | NUVL | Chief Development Officer | Mar 6 '25 | Sell | $71.89 | 34,000 | $2,443,578.02 | 48,934 | |
| Shair Matthew | NUVL | Director | Feb 24 '25 | Sell | $78.38 | 2,000 | $156,863.60 | 216,522 | |
| Porter James Richard | NUVL | President and CEO | Feb 18 '25 | Sell | $78.73 | 27,000 | $2,118,336.00 | 249,550 | |
| Shair Matthew | NUVL | Director | Jan 27 '25 | Sell | $83.51 | 2,000 | $165,575.90 | 216,522 |
Latest Nuvalent Inc. News
NUVL Breaking Stock News: Dive into NUVL Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying
Insider Monkey
3 days ago
Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
PR Newswire
3 days ago
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting
Insider Monkey
25 days ago
Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now?
PR Newswire
25 days ago
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Insider Monkey
a month ago
Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy
PR Newswire
a month ago
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
MT Newswires
a month ago
Nuvalent Insider Sold Shares Worth $2,048,562, According to a Recent SEC Filing
Compare NUVL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVL Nuvalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.